From Research to Clinical Impact: Dr. Jan Rijn Zeevaart’s Role in Advancing Nuclear Medicine
Bridging Radiochemistry and Patient Care
Dr. Jan Rijn Zeevaart has built a distinguished career turning advanced radiochemistry research into tangible benefits for patients in South Africa and beyond. After completing his PhD at Delft University of Technology (TU Delft) in 2001, he joined the South African Nuclear Energy Corporation (Necsa), where he has led the Radiochemistry Department since 2002. Today, as Divisional Executive for Research and Technology Development at Necsa, he oversees wide-ranging research programmes while continuing his pioneering work in radiopharmaceutical innovation.
Recognised as a B2-rated researcher by the National Research Foundation of South Africa, Dr. Zeevaart has authored more than 100 international publications, presented at over 150 scientific conferences, and holds six patents in radiochemistry and radiopharmaceutical sciences. His focus on designing new radioligands has advanced the ability to diagnose and treat cancers with unprecedented precision.
National Leadership and Innovation in Radiopharmaceuticals
Dr. Zeevaart’s leadership has been instrumental in making South Africa a hub for theranostics and molecular imaging. From 2016 to 2020, he served as Champion of the Nuclear Medicine Research Infrastructure (NuMeRI), helping to establish three national research nodes and guiding the design of the state-of-the-art facility at Steve Biko Academic Hospital. He also coordinated the Nuclear Technologies in Medicine and Biosciences Initiative (NTeMBI), aligning scientific research with clinical application.
At Necsa, he spearheaded the development of isotope production processes now managed by NTP Radioisotopes SOC, including the fission-based I‑131 production line that has operated for 25 years. This achievement not only supported medical innovation but also generated over 50 million rand annually in foreign revenue. In collaboration with Prof. Mike Sathekge, Dr. Zeevaart helped develop infection imaging radiopharmaceuticals that are now in clinical use, demonstrating his ability to translate research into real-world medical solutions.
Recognition and a Lasting Global Contribution
Dr. Zeevaart’s contributions have earned him widespread recognition. He received the Raikes Medal (2007) from the South African Chemical Institute, the Marie Curie Award (2018) from the European Association of Nuclear Medicine and Molecular Imaging, and the Top Intellectual Creator Award (2019) from the Department of Science and Technology of South Africa. These accolades underscore his status as a leader in radiopharmaceutical research and innovation.
Today, through his dual focus on cutting-edge radiochemistry research and national infrastructure development, Dr. Zeevaart continues to strengthen Africa’s role in the global field of theranostics and nuclear medicine. His work ensures that discoveries made in the laboratory are transformed into therapies that directly improve patient outcomes.